A phase II study: Efficacy of the gene therapy of the MVA E2 recombinant virus in the treatment of precancerous lesions (NIC I and NIC II) associated with infection of oncogenic human papillomavirus

Human Gene Therapy

Volumn 13, Issue 9, 2002, Pages 1127-1140

  Gutierrez, Carlos Manual Corona ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; DIPHENHYDRAMINE; PARACETAMOL; RECOMBINANT DNA; SALBUTAMOL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DYSPNEA; EVALUATION; FEMALE; FEVER; FOLLOW UP; HUMAN; HUMAN TISSUE; HYPERSENSITIVITY; HYPOTENSION; PHASE 2 CLINICAL TRIAL; PRECANCER; SIDE EFFECT; TREATMENT OUTCOME; VACCINIA VIRUS; VIRUS INFECTION; VIRUS RECOMBINANT; WART VIRUS; CLINICAL PROTOCOL; GENE THERAPY; GENETICS; PAPILLOMA VIRUS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPES; PAPILLOMAVIRUS; VACCINIA VIRUS;

CLINICAL PROTOCOLS; GENE THERAPY; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; TUMOR VIRUS INFECTIONS; VACCINIA VIRUS;

EID: 0037053616     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303402753812520     Document Type: Article

References (48)

1. Papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions
2. The causal link between human papillomavirus and invasive cervical cancer: A population study based in Colombia and Spain
3. Cervical cancer and human papillomavirus: Epidemiological evidence and perspectives for prevention
4. Characterization of human papillomavirus types in condylomata acuminata in children by in situ hybridization
5. Papillomavirus in anogenital cancer: The dilemma of epidemiologic approaches
6. La detección oportuna del cáncer cérvico uterino
7. Papillomavirus humanos y cáncer cérvico uterino
8. Early promoters of genital and cutaneos human papillomaviruses are differentially regulated by the bovine papillomavirus type 1 E2 gene product
9. Inhibition of cervical carcinoma cell line proliferation by the introduction of a bovine papillomavirus regulatory gene
10. Functional analysis of E2-mediated repression of the HPV 18 P105 promoter
11. Genome amplification of human papillomavirus types 16 and 18 in cervical carcinomas in related to retention of E1/E2 genes
12. Both episomal and integrated forms of human papillomavirus type 16 are involved in invasive cervical cancers
13. Growth inhibition of human papillomavirus 16 DNA-positive mouse tumor by antisense RNA transcribed from U6 promoter
14. Effects of human papillomavirus type 18-specific antisense oligonucleotides on the transformed phenotype of human carcinoma cell lines
15. Construction and characterization of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer
16. Coestimulation enhances the active immunotherapy effect of recombinant anticancer vaccines
17. B70 antigen is a second ligand for CTLA-4 and CD28
18. Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7
19. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation
20. Supression of cellular proliferation by the papillomavirus E2 protein
21. 105 promoters
22. Immunization with non-structural proteins E1 and E2 of cottontail rabbit papillomavirus stimulates regression of virus-induced papillomas
23. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: Implications for use as a human vaccine
24. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime
25. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: A murine tumor model
26. Recombinant vaccinia virus: Immunization against multiple pathogens
27. MVA - Stufenimpfung gegen Pocken
28. Virulenz und immunogenität eines modifizierten vaccinia-virus (Stamm MVA)
29. Studies on poxvirus infection in irradiated animals
30. Non replicating vaccinia vector efficiently expresses recombinant genes
31. Non-replicating vector efficiently expresses bacteriophage T7 polymerase
32. Therapeutic effects of bovine enterovirus infection on rabbits with experimentally induced adult T cell leukaemia
33. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus
34. Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: Enhanced CD81 T cell immunogenicity and protective efficacy in the influenza and malaria models
35. Use of apathogenic vaccinia virus MVA expressing EHV-1 gC as basis of a combined recombinant MVA/DNA vaccination scheme
36. Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge
37. Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies
38. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model
39. Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA
40. Vaccination with recombinant modified vaccinia virus Ankara protects against measles virus infection in the mouse and cotton rat model
41. Bovine papillomavirus contains multiple transforming genes
42. Human tumor growth is inhibited by vaccinia virus carrying the E2 gene of bovine papillomavirus
43. Restriction mapping and physical characterization of the cottontail rabbit papillomavirus genome in transplantable VX2 and VX7 domestic rabbit carcinomas
44. A recombinant vaccinia virus containing the papilloma E2 protein promotes tumor regression by stimulating macrophage antibody-dependent cytotoxicity